Himedi COO on South Korea’s preventive health model, the changing longevity traveler and why one diagnostic day is only the beginning.
For decades, South Korea’s medical tourism reputation has been closely associated with aesthetics – dermatology, cosmetic procedures and the formidable international reach of K-beauty. Now, another kind of traveler is arriving: one less interested in changing how aging looks than in establishing how well they are aging in the first place.
Americans are among those traveling to South Korea for comprehensive preventive health screening, accessing combinations of bloodwork, advanced imaging, cardiovascular assessment, cancer screening and physician consultation within a highly compressed timeframe. Himedi, a government-licensed medical tourism platform, helps international patients navigate South Korea’s healthcare system, and interest is increasingly coming from consumers who see diagnostics not simply as a search for disease, but as part of a broader healthspan strategy.
Longevity.Technology: After spending decades becoming extraordinarily good at helping the world look younger, South Korea may have found itself unusually well equipped to help it interrogate whether it is aging well. There is a certain irony here, but also a serious structural point: the infrastructure that supports high-throughput aesthetic medicine – concentrated clinical expertise, transparent pricing and a consumer accustomed to paying for convenient access – sits alongside a healthcare system in which preventive screening is already normalized at population level. For American longevity consumers, some of whom are now crossing the Pacific for extensive imaging, bloodwork and cancer screening, that raises a rather uncomfortable question: why does crossing an ocean make preventive medicine easier to buy? Yet diagnostics, however comprehensive, are only the opening move. Finding an anomaly is one thing; understanding its significance, acting on it and adhering to whatever intervention follows is quite another – agency matters, and longevity is necessarily longitudinal. A biological age score, metabolic profile or suspicious scan has limited healthspan value if it becomes an interesting data point rather than the beginning of sustained clinical action, particularly when the patient returns home and becomes, as Ban puts it, “the general contractor” of their own follow-up. To find out more about South Korea’s pivot from aesthetic tourism to healthspan destination, the changing profile of the longevity traveler and how one day of intensive diagnostics can translate into years of preventive care, we sat down with Himedi COO and Cofounder William Ban.
From looking young to functioning young
Ban sees less of a leap between South Korea’s established aesthetic tourism industry and preventive health tourism than might first appear. Both, he says, rely on the same operational architecture.
“What people underestimate is that aesthetic tourism and longevity screening share the same underlying machine: high patient throughput, a consumer who pays cash and expects a concierge experience, transparent packaged pricing, and same-day service,” he told Longevity.Technology. “Korea spent two decades building that operating system for dermatology and cosmetic work. Pointing it at systemic diagnostics is less a reinvention than a re-aiming.”
That re-aiming is occurring through established hospital-affiliated screening centers, increasingly marketed to international longevity consumers, alongside premium anti-aging and wellness centers and boutique clinics. South Korea attracted 2.01 million international patients in 2025, according to Ban; while aesthetics continues to dominate numerically, he says diagnostic intent is growing.
Prevention by design
The difference is not simply one of price. Ban points to South Korea’s density of hospital beds and imaging equipment, co-location of MRI, CT, ultrasound and endoscopy and, crucially, a national system in which routine screening of healthy adults is already embedded.
“Korea’s national insurance entitles every adult to a general health screening on a fixed schedule, with participation around 74 to 78 percent of the eligible population, plus a national program covering six cancers,” he said. “That built a whole industry of purpose-designed checkup centers optimized for moving healthy people through comprehensive testing efficiently. The US built its system around treating the sick, so it never developed that muscle at scale.”
For Americans accustomed to referrals, prior authorizations and diagnostics scattered across different providers, the contrast can be marked. “The barriers aren’t clinical, they’re structural,” Ban said, pointing to reimbursement, liability and fragmented facilities as factors that make an equivalent single-day pathway difficult to reproduce in the US.
A different traveler
Nor is the market confined to the traditional executive physical demographic. Ban describes two cohorts: patients in their 50s and 60s seeking reassurance and early disease detection, and a younger group in their 30s and 40s already accustomed to wearables, continuous monitoring and quantified-health data.
“They’re not scared; they’re curious and data-driven,” he said. Speaking to what draws that younger group specifically, Ban points to a more granular hunger for data: “The younger cohort asks about biological age, metabolic data, and trend lines they can act on, and they’re the ones pulling the market toward true longevity metrics.”
Age, but make it clinical
South Korean screening programs are responding. Alongside MRI, low-dose CT, endoscopy, cardiac calcium scoring and extensive bloodwork, Ban says biological age scoring is increasingly incorporated into checkups, with metabolic testing, body composition and AI-supported approaches also available.
That confidence rests on scale most Western clinics can’t match: Korean researchers have built and validated aging-clock models directly against a national screening database of roughly four million people, the kind of population-level dataset that lets a bio-age metric be offered as standard rather than piloted as a boutique add-on.
There is, however, an important distinction between biological age derived from clinical biomarkers, organ function, body composition and imaging, and epigenetic clocks based on DNA methylation. The latter, Ban notes, remain less standardized as routine offerings – in South Korea as elsewhere – while validation continues.
The problem after the plane lands
If a concentrated diagnostic experience sounds neatly self-contained, longevity is anything but. The useful endpoint of screening is not the report; it is what happens because of it.
“This is the real challenge, and I don’t want to wave it away,” Ban said. “A deep diagnostic baseline is enormously valuable, but longevity is longitudinal, and a single brilliant day in Seoul can create findings that need follow-up thousands of miles away.”
Himedi provides clients with an English-language digital report intended for use with their physician at home, but Ban acknowledges that subsequent care remains largely patient-managed. The company is in partnership discussions with US primary care networks to create a more formal handover and is planning US checkup centers as part of an attempt to close that continuity gap.
Where the journey really starts
A healthspan economy built around increasingly detailed measurement will eventually be judged less by how much it can reveal than by what people and their clinicians can usefully do with the information. That means evidence, interpretation and sustained adherence – decidedly less glamorous than a trans-Pacific medical itinerary, perhaps, but rather more consequential.
As Ban puts it: “The future isn’t simply flying to Korea once for a checkup. It’s using a high-density, affordable baseline as the entry point to an ongoing relationship, with the longitudinal care living close to home.”
